Eluxadoline: First Global Approval.

Article Details

Citation
Copy to clipboard

Garnock-Jones KP

Eluxadoline: First Global Approval.

Drugs. 2015 Jul;75(11):1305-10. doi: 10.1007/s40265-015-0436-4.

PubMed ID
26149369 [ View in PubMed
]
Abstract

Eluxadoline (Viberzi()), developed by Actavis (now Allergan), is an orally administered, first-in-class compound that functions as both a micro-opioid receptor agonist and a delta-opioid receptor antagonist, and is indicated for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D) in adults. The agent was originally developed by Janssen Pharmaceutica. Eluxadoline has been approved in the US, and submissions to other global authorities are being contemplated or planned. This article summarizes the milestones in the development of eluxadoline leading to this first approval for IBS-D.

DrugBank Data that Cites this Article

Drugs